Identification of Biomarkers and Novel Pathways of Alcoholic Liver Disease by Leveraging Metabolomics, Tissue Imaging Mass Spectrometry, and Integrative Machine Learning

利用代谢组学、组织成像质谱和综合机器学习鉴定酒精性肝病的生物标志物和新途径

基本信息

  • 批准号:
    10221329
  • 负责人:
  • 金额:
    $ 15.06万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2020
  • 资助国家:
    美国
  • 起止时间:
    2020-04-10 至 2022-03-31
  • 项目状态:
    已结题

项目摘要

Abstract The induces flu-like treatment health, 1,919,430 societal people COVID-19. disease means infected extremely ventilators, SARS-CoV-2 . We propose to identify alterations in the plasma metabolome of patients experiencing different levels of severity of COVID-19. Such changes should be pivotal in allowing the prediction of the severity of the patient COVID-19 symptoms and also provide mechanistic information about the disease and its progression. In addition to our expertise in metabolomics, we are able to carry out this project because we have access to samples from the Yale New Haven Hospital System via the IMPACT Biorepository. This repository stores human specimens related to emerging respiratory viral infections (with a particular focus on COVID-19) in order to support research on factors related to viral expression, transmission, disease severity, progression, and susceptibility. The directors of the biorepository are co-investigators in this supplement. As such, we are in unique position to perform this novel research because we have: (a) the infrastructure to conduct the metabolomic analyses and we have already developed the methodologies, (b) access to COVID-19 patient plasma samples stored at the IMPACT (Implementing medical and public health actions against coronavirus in Connecticut) Biorepository (and associated patient records), (c) assembled an extraordinary team that includes expertise in metabolomics, virology, pulmonary and infectious disease, and immunology. of this supplement current pandemic caused by SARS-CoV-2 is of major concern because (i) it is highly contagious, (ii) it a spectrum of adverse health consequences (collectively known as COVID-19) that range from mild symptoms (fever, chills, cough) to life-endangering pneumonia and SARS, and (iii) there is no effective or vaccine to prevent it. To date, the SARS-CoV-2 pandemic has had devastating effects on public with an international mortality rate of 5.8% in infected individuals. As of June 6, 2020, the U.S. has cases and a mortality rate of 5.7%. Measures taken to stem the pandemic have paralyzed normal activities and crippled national and international economies. I n the early stages of the pandemic, older and individuals with specific underlying medical conditions were shown to be more vulnerable to More recently, it has become apparent that younger, ostensibly healthy individuals likely carry the and may succumb/progress to the more serious manifestations of COVID-19. Currently, there is no to reliably predict the severity of COVID-19 symptoms (or the course of COVID-19) in individuals by SARS-CoV-2 . This represents a significant knowledge deficit. Having such information would be helpful in triaging patients and allowing more efficient utilization of limited health resources, e.g., ICU beds, and medical personnel. N or that are associated with the various stages of COVID-19 o studies have investigated metabolic alterations caused by
摘要

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

VASILIS VASILIOU其他文献

VASILIS VASILIOU的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('VASILIS VASILIOU', 18)}}的其他基金

Administrative Core
行政核心
  • 批准号:
    10361890
  • 财政年份:
    2022
  • 资助金额:
    $ 15.06万
  • 项目类别:
Emerging Water Contaminants: Investigating and Mitigating Exposures and Health Risks
新出现的水污染物:调查并减轻暴露和健康风险
  • 批准号:
    10361885
  • 财政年份:
    2022
  • 资助金额:
    $ 15.06万
  • 项目类别:
Emerging Water Contaminants: Investigating and Mitigating Exposures and Health Risks
新出现的水污染物:调查并减轻暴露和健康风险
  • 批准号:
    10698003
  • 财政年份:
    2022
  • 资助金额:
    $ 15.06万
  • 项目类别:
Administrative Core
行政核心
  • 批准号:
    10698032
  • 财政年份:
    2022
  • 资助金额:
    $ 15.06万
  • 项目类别:
Identification of Biomarkers and Novel Pathways of Alcoholic Liver Disease by Leveraging Metabolomics, Tissue Imaging Mass Spectrometry, and Integrative Machine Learning
利用代谢组学、组织成像质谱和综合机器学习鉴定酒精性肝病的生物标志物和新途径
  • 批准号:
    10382633
  • 财政年份:
    2020
  • 资助金额:
    $ 15.06万
  • 项目类别:
Summer Research Experience in Environmental Health (SREEH)
环境健康暑期研究经验(SREEH)
  • 批准号:
    10112911
  • 财政年份:
    2019
  • 资助金额:
    $ 15.06万
  • 项目类别:
Glutathione Monoesters to Counteract Ocular Chemical Injury
谷胱甘肽单酯对抗眼部化学损伤
  • 批准号:
    9001771
  • 财政年份:
    2015
  • 资助金额:
    $ 15.06万
  • 项目类别:
The role of GSH in cornea and lens development
GSH 在角膜和晶状体发育中的作用
  • 批准号:
    8891008
  • 财政年份:
    2014
  • 资助金额:
    $ 15.06万
  • 项目类别:
The role of ALDH1B1 in ethanol metabolism and colon cancer
ALDH1B1 在乙醇代谢和结肠癌中的作用
  • 批准号:
    8704693
  • 财政年份:
    2014
  • 资助金额:
    $ 15.06万
  • 项目类别:
A Novel Aldehyde Dehydrogenase (ALDH16A1) in Gout
痛风中的新型醛脱氢酶 (ALDH16A1)
  • 批准号:
    8634470
  • 财政年份:
    2014
  • 资助金额:
    $ 15.06万
  • 项目类别:

相似海外基金

Uncovering the Role of Retinoic Acid Receptor Beta in Alcoholic Liver Diseases
揭示视黄酸受体β在酒精性肝病中的作用
  • 批准号:
    10019450
  • 财政年份:
    2019
  • 资助金额:
    $ 15.06万
  • 项目类别:
Uncovering the Role of Retinoic Acid Receptor Beta in Alcoholic Liver Diseases
揭示视黄酸受体β在酒精性肝病中的作用
  • 批准号:
    9896234
  • 财政年份:
    2019
  • 资助金额:
    $ 15.06万
  • 项目类别:
Alcoholic Liver Diseases: Damage, Repair and Stem Cell Regeneration
酒精性肝病:损伤、修复和干细胞再生
  • 批准号:
    7990196
  • 财政年份:
    2010
  • 资助金额:
    $ 15.06万
  • 项目类别:
Alcoholic Liver Diseases: Damage, Repair and Stem Cell Regeneration
酒精性肝病:损伤、修复和干细胞再生
  • 批准号:
    8299173
  • 财政年份:
    2010
  • 资助金额:
    $ 15.06万
  • 项目类别:
Alcoholic Liver Diseases: Damage, Repair and Stem Cell Regeneration
酒精性肝病:损伤、修复和干细胞再生
  • 批准号:
    8102173
  • 财政年份:
    2010
  • 资助金额:
    $ 15.06万
  • 项目类别:
Alcoholic Liver Diseases: Damage, Repair and Stem Cell Regeneration
酒精性肝病:损伤、修复和干细胞再生
  • 批准号:
    8494464
  • 财政年份:
    2010
  • 资助金额:
    $ 15.06万
  • 项目类别:
Alcoholic Liver Diseases: Damage, Repair and Stem Cell Regeneration
酒精性肝病:损伤、修复和干细胞再生
  • 批准号:
    8693870
  • 财政年份:
    2010
  • 资助金额:
    $ 15.06万
  • 项目类别:
Screening of food components for the prevention of alcoholic liver diseases and their application
预防酒精性肝病的食品成分筛选及其应用
  • 批准号:
    21500783
  • 财政年份:
    2009
  • 资助金额:
    $ 15.06万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Contribution of transforming growth factor-a to thr development of hepatic fibrosis in alcoholic liver diseases
转化生长因子-a对酒精性肝病肝纤维化发展的贡献
  • 批准号:
    09670560
  • 财政年份:
    1997
  • 资助金额:
    $ 15.06万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Immunological mechanism on the generation of alcoholic liver diseases
酒精性肝病发生的免疫学机制
  • 批准号:
    03670349
  • 财政年份:
    1991
  • 资助金额:
    $ 15.06万
  • 项目类别:
    Grant-in-Aid for General Scientific Research (C)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了